Vitamin D status and chemotherapy-induced peripheral neuropathy: A scoping review.

This article focuses on the association between vitamin D (VD) status and chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing cytotoxic chemotherapy. A scoping review of eleven observational studies found that patients with breast or cervical cancer receiving paclitaxel, those with multiple myeloma treated with bortezomib, thalidomide, and/or lenalidomide, and patients on oxaliplatin-based regimens for gastrointestinal tumors exhibited higher incidence and severity of CIPN when serum VD levels were low. The review suggests that VD's neuroprotective, neuroregenerative, and anti-inflammatory properties may play a protective role against CIPN development. However, the evidence is limited by study heterogeneity and observational designs, highlighting the need for standardized VD deficiency cutoffs and randomized controlled trials to clarify VD's clinical implications in CIPN prevention and management.